Kouba

Researchers are studying hereditary angioedema HAE, a rare condition causing sudden swelling under the skin and inside the body, such as in the belly, throat, or genitals. This swelling is due to temporary blood vessel leakage and does not cause itching or hives. The study focuses on testing the effectiveness of measuring the function of a protein called C1-inhibitor C1INH alone to diagnose two types of HAE HAE-C1INH-Type1 and HAE-C1INH-Type2, compared to the standard tests used in Algeria. The study also aims to establish a reference value for this test and collect health background information from participants. During the study, all participants will undergo two diagnostic methods the new test measuring C1INH function alone using the Technochrom C1-INH Kit and the standard of care SoC tests, which include measuring C4 and C1-INH antigenic levels and function. For participants with new or conflicting test results, a second confirmatory test will be performed, and if needed, a third test. Participants suspected of HAE or family members of known HAE cases will be enrolled. They may visit the clinic up to three times, with no further follow-up planned after testing. Participants will provide health history data, including age at diagnosis, symptoms, diagnostic delays, and referral pathways. Researchers will measure the accuracy and reliability of the new test compared to standard methods. The main outcome is the sensitivity and specificity of the Technochrom test for diagnosing HAE. The study will last up to 12 months for each participant, with no additional long-term follow-up.

Researchers are conducting a prospective, multicenter observational study called SAFRO 2202 ALG-Lung Cancer Registry to gather detailed information on lung cancer patients in Algeria. This study focuses on various types of lung cancer, including non-small cell lung cancer, small cell lung cancer, and carcinoid tumors. The goal is to collect real-world data on the epidemiology, clinical features, pathology, molecular markers, and treatment patterns to improve lung cancer care nationwide. The study involves adult patients aged 18 years and older who have been diagnosed with lung cancer at the time of enrollment or within the prior 12 months. Participants are managed fully within oncology or pulmonology departments at 21 public and university hospitals across Algeria. Data are collected during routine clinical care visits without any additional study-specific procedures or interventions. Information such as tumor histology, molecular profiles, staging, and treatment choices are recorded securely in an electronic case report form. During the study, researchers will track clinical outcomes including treatment toxicities, response rates, progression-free survival, time to treatment discontinuation, and overall survival. Data collection aligns with standard care and includes demographic details, medical history, risk factors, and performance status. The study plans to enroll about 1,500 patients per year over 30 months, with each patient followed for at least 12 months to support future health planning and lung cancer management improvements in Algeria.

Researchers are investigating autoinflammatory diseases AID, which involve recurring inflammatory episodes without infection, cancer, or adaptive immune system problems. This study focuses on both monogenic hereditary periodic syndromes and polygenic or multifactorial AID, including rare conditions like Behets disease, Still disease, Schnitzlers disease, PFAPA syndrome, chronic recurrent multifocal osteomyelitis, non-infectious uveitis and scleritis, among others. The goal is to gather detailed data to improve understanding and management of these rare diseases through an international collaboration. The study uses the AIDA registry, a secure online platform for collecting demographic, genetic, clinical, laboratory, radiologic, and therapeutic information. Data are gathered retrospectively and prospectively during routine clinical visits scheduled every 3-6 months. Eleven registries focus on different AID conditions, enabling comprehensive data collection to identify clinical patterns, treatment impacts, and long-term outcomes over a period of at least 10 years. Participants provide information during their usual care visits, allowing researchers to track changes in disease activity, organ involvement, inflammatory markers, visual function, pain levels, fatigue, fertility, and socioeconomic factors. The study monitors these outcomes over multiple timepoints up to 120 months. Data privacy is ensured by pseudonymizing patient information. This registry supports multiple clinical studies and aims to enhance knowledge, awareness, and future research on autoinflammatory diseases worldwide.

Researchers are studying pregnancies that occurred before the diagnosis of systemic lupus erythematosus SLE in women who were later diagnosed with this condition. This observational, retrospective cohort study aims to understand maternal and fetal outcomes as well as systemic signs of SLE present before or during pregnancy. The diagnosis of SLE is based on established criteria including the ACR 1997 and renal histological findings. The study collects information from medical records and patient interviews during medical visits. Data on all pregnancies before and after the diagnosis of SLE will be gathered, including obstetrical events and features such as anthropometric, biological, immunological, and histological data when available. The severity and activity of SLE after diagnosis will also be assessed using recommended tools. Participants will be evaluated from the beginning of each pregnancy until three months after childbirth. Researchers will measure the prevalence of obstetrical events before SLE diagnosis and compare pregnancy outcomes before and after diagnosis. The study involves reviewing medical histories and asking questions during visits to better understand how SLE affects pregnancies and disease severity over time.

Researchers are conducting an observational study to understand how a pertuzumab biosimilar is used and its clinical results in people with HER2-positive breast cancer. The study focuses on two groups patients receiving this treatment before surgery neoadjuvant setting and those receiving it as first-line therapy for metastatic breast cancer. The study aims to assess important outcomes including pathological complete response, disease-free survival, progression-free survival, overall survival, treatment response, and safety across both groups. This non-interventional study will include about 1,000 patients across multiple centers, with 500 patients in each group. Cohort 1 involves patients treated with the pertuzumab biosimilar before surgery for HER2-positive breast cancer, while Cohort 2 includes those treated in the first-line metastatic setting. All treatments are part of routine clinical care, not controlled by the study. No experimental interventions are assigned by the researchers. Participants will be followed for up to 36 months to observe treatment use, therapy lines, duration, and how response is assessed. Clinical outcomes such as pathological complete response in the neoadjuvant group, disease-free survival, progression-free survival, treatment response, overall survival, and adverse events will be monitored for up to 24 months. Data will be collected from medical records and routine care, with safety and tolerability evaluated according to standard criteria.

Researchers are conducting an observational study to understand the demographic, epidemiological, clinical, and outcome characteristics of patients with gastric cancer in Algeria. The study also aims to examine how these patients are diagnosed and treated in various oncology departments. The research gathers both prospective and retrospective data to provide a detailed overview of gastric cancer management in this population. This study collects data mainly through medical records and brief patient interviews lasting about 30 minutes. It involves approximately 1,000 patients with a confirmed diagnosis of gastric cancer. The data collection is non-interventional, meaning it does not involve any treatment or changes to patient care but focuses on describing existing diagnostic and therapeutic practices. Participants will provide information once during an initial visit, where researchers will assess demographic, sociological, epidemiological, and clinical features, along with disease progression. The study also records diagnostic methods and treatment approaches used. All collected data will be anonymized to protect patient privacy and used solely for research purposes. Participation duration corresponds to the initial data collection visit.

Researchers are studying prostate cancer patients in Algeria to describe their demographic, clinical, diagnostic, and treatment characteristics. This observational study focuses on patients with confirmed prostate cancer and aims to analyze how the disease is diagnosed and managed in local oncology centers. Data will be collected through medical records and patient interviews lasting about 30 minutes. The study plans to enroll up to 500 patients and will use a standardized electronic form to gather information on medical history, clinical features, diagnostic tests, and treatment methods. All collected data will be anonymized for research purposes. Participants will undergo a one-time evaluation including interviews and medical record reviews. Researchers will assess socio-demographic details, family cancer history, lifestyle factors like smoking and alcohol use, symptoms, diagnostic procedures, and treatment approaches. The main outcomes include symptom scores and disease status at the initial visit. The study will also monitor time intervals from symptom onset to diagnosis and treatment, and track any adverse events reported by patients.